Spots Global Cancer Trial Database for Weekly Docetaxel and Fixed-Dose Rate Gemcitabine Combination Chemotherapy
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Weekly Docetaxel and Fixed-Dose Rate Gemcitabine Combination Chemotherapy
Official Title: PhaseⅡ Study of Weekly Docetaxel and Fixed-Dose Rate Gemcitabine in Patient With Previously Treated Advanced Soft Tissue and Bone Sarcoma Prospective, Open Label, Multi-Institutional
Study ID: NCT00807261
Conditions
Interventions
Study Description
Brief Summary: To determine the activity of weekly Docetaxel and Gemcitabine in patients with advanced soft tissue sarcoma previously treated with anthracycline and/or ifosfamide 1. Primary endpoint: response rate 2. Secondary endpoint: progress-free survival, overall survival, safety
Detailed Description:
Keywords
Eligibility
Minimum Age: 16 Years
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Contact Details
Name: Jin-hee Ahn
Affiliation: AIDS Malignancy Consortium
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
